Cell therapy for hard-to-treat autoimmune hemolytic anemia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This early-phase trial tests a new cell therapy (UCAR T cells) that targets specific markers on your immune cells (called CD19 and BCMA) to help stop your body from attacking your own red blood cells. It's for people with autoimmune hemolytic anemia that hasn't responded to multiple standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have autoimmune hemolytic anemia (AIHA) — a condition where your immune system destroys your red blood cells — and it must have come back or not improved after at least three prior treatments.
- Your blood tests must show a certain type of white blood cell (CD19 or BCMA positive B cells).
- Your kidneys, liver, and blood counts must be within safe limits for this study.
- You must not have an active, uncontrolled infection, a recent cancer, or severe heart problems.
- Women who can become pregnant and men with partners who can become pregnant must agree to use birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called UCAR T-cells, which are immune cells engineered to target and destroy the B cells causing your body to attack its own red blood cells. It's designed for patients whose autoimmune hemolytic anemia hasn't responded to at least 3 standard treatments.
This study tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia that hasn't improved after other treatments. The goal is to see if this therapy can help control the disease and be safe.
This trial tests a new type of cell therapy called Inaticabtagene Autoleucel (a personalized treatment made from your own immune cells) for people with autoimmune hemolytic anemia that has not improved after three or more prior treatments. The goal is to see if this therapy can stop the immune system from destroying red blood cells and help increase your hemoglobin levels.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This trial tests a new treatment using your own immune cells (CAR T-cells) to stop them from attacking your red blood cells. It is for people with autoimmune hemolytic anemia or Evans syndrome who have not improved after at least 3 previous treatments.
This study tests a new treatment using your own immune cells, modified to target and destroy the faulty cells causing your anemia. It aims to provide a lasting remission for people whose disease has not responded to standard treatments.
Hear when a new Relapsed / Refractory Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.